Rhea Methylprednisolone

Rhea Methylprednisolone





Concise Prescribing Info
Endocrine disorders: Primary or secondary adrenocortical insufficiency; congenital adrenal hyperplasia; non-suppurative thyroiditis; hypercalcemia associated w/ cancer. Non-endocrine disorders: Adjunctive therapy for short-term use in rheumatic disorders; during exacerbation or as maintenance of collagen diseases; dermatologic, ophth, resp, neoplastic & GI diseases; allergic & edematous states; hematologic disorders; nervous system; organ transplantation. TB meningitis w/ subarachnoid or impending block when used w/ appropriately anti-TB chemotherapy. Trichinosis w/ neurologic or myocardial involvement.
Dosage/Direction for Use
Individualized dosage. Multiple sclerosis 200 mg/day. Cerebral edema 200-1,000 mg/day. Organ transplantation Up to 7 mg/kg/day.
Should be taken with food.
Hypersensitivity. Systemic fungal infections. Live or live, attenuated vaccines.
Special Precautions
Not to be used to treat traumatic brain injury. May increase susceptibility, may mask signs of infections & new infections may appear. Patients w/ suppressed immune system (eg, chicken pox & measles), latent TB or tuberculin reactivity; septic shock; hyperthyroidism; diabetes; seizure disorders, myasthenia gravis; ocular herpes simplex; existing CV risk factors, CHF, HTN; disorders of neuromuscular transmission (eg, myasthenia gravis). Response to killed or inactivated vaccines may be diminished. Kaposi's sarcoma, acute adrenal insufficiency, central serous chorioretinopathy; thrombosis including venous thromboembolism; acute pancreatitis; hepatobiliary disorders; acute myopathy; pheochromocytoma crisis. Allergic reactions (eg, angioedema); psychic derangements may occur. BP elevation, salt & water retention, increased excretion of K & Ca. Avoid in patients w/ Cushing's disease. Concomitant use w/ NSAIDs & aspirin; anticholinergics eg, neuromuscular blocking drugs (eg, pancuronium). May suppress growth & produce pancreatitis in childn. Prolonged use. Renal insufficiency. May affect ability to drive or operate machinery. Pregnancy & lactation. Infants & childn.
Adverse Reactions
Opportunistic infection, infection, peritonitis; leukocytosis; drug hypersensitivity, anaphylactic & anaphylactoid reaction; Cushingoid, hypopituitarism, steroid w/drawal syndrome; metabolic acidosis, Na & fluid retention, hypokalemic alkalosis, dyslipidemia, impaired glucose tolerance, increased insulin requirement (or oral hypoglycemic agents in diabetics), lipomatosis, increased appetite (increased wt), affective disorder (including depressed mood, euphoric mood, affect lability, drug dependence, suicidal ideation), psychotic disorder (including mania, delusion, hallucination & schizophrenia), psychotic behavior; mental disorder, change personality, confusional state, anxiety, mood swings, abnormal behavior, insomnia, irritability; epidural lipomatosis, increased intracranial pressure [w/ papilledema (benign intracranial HTN)], seizure, amnesia, cognitive disorder, dizziness, headache; chorioretinopathy, cataract, glaucoma, exophthalmos; vertigo; cardiac failure congestive (in susceptible patients); thrombosis, HTN, hypotension; pulmonary embolism, hiccups; peptic ulcer, intestinal perforation, gastric hemorrhage, pancreatitis, ulcerative esophagitis, esophagitis, abdominal distention & pain, diarrhea, dyspepsia, nausea; angioedema, hirsutism, petechiae, ecchymosis, skin atrophy, erythema, hyperhidrosis, skin striae, rash, pruritus, urticaria, acne; muscular weakness, myalgia, myopathy, muscle atrophy, osteoporosis, osteonecrosis, pathological fracture, neuropathic arthropathy, arthralgia, growth retardation; irregular menstruation; impaired healing, peripheral edema, fatigue, malaise; increased IOP, urine Ca, ALT/AST, blood alkaline phosphatase & blood urea; decreased carbohydrate tolerance & blood K; suppression of skin tests reaction; spinal compression fracture, tendon rupture.
Drug Interactions
Increased risk of developing GI ulcers & bleeding w/ NSAIDs. Decreased hepatic clearance & increased plasma conc w/ CYP3A4 inhibitors. Increased hepatic clearance & decreased plasma conc w/ CYP3A4 inducers. May increase acetylation rate & clearance of INH. May enhance or diminish effects of anticoagulants. May influence effect of anticholinergics eg, neuromuscular blocking drugs. Antagonism of neuromuscular blocking effects of pancuronium & vecuronium. May reduce anticholinesterase effect in myasthenia gravis. Increased plasma conc w/ PIs & may induce metabolism of HIV-PIs. Aminoglutethimide-induced adrenal suppression may exacerbate endocrine changes. Increased plasma conc & convulsions may occur w/ cyclosporine. May increase clearance of high-dose aspirin. Increased risk of hypokalemia w/ K-depleting agents (eg, diuretics); amphotericin B, xanthines or β2-agonists. CYP3A4 substrates & non-CYP3A4-mediated effects; rifampin, carbamazepine, phenobarb, phenytoin, antidiabetic drugs, aprepitant, fosaprepitant; itraconazole, ketoconazole; diltiazem, OCs (ethinylestradiol/norethindrone); grapefruit juice; cyclosphamide, tacrolimus; clarithromycin, erythromycin, troleandomycin.
ATC Classification
H02AB04 - methylprednisolone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Rhea Methylprednisolone tab 16 mg
30's (P897.75/box)
Rhea Methylprednisolone tab 4 mg
100's (P918.75/box)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in